Search results
ASCO 2024: What's New in Breast Cancer Research?
Medscape· 2 days agoDrs Alexandra Thomas and Virginia Kaklamani discuss highlights in breast cancer research from the ASCO 2024 Annual Meeting.
With new Enhertu data, an ADC could overtake chemo in breast cancer
BioPharma Dive via Yahoo Finance· 5 days agoStudy participants had already received one hormone therapy and a type of drug called a CDK 4/6...
AstraZeneca’s breast cancer trial shows ‘unprecedented’ results | Honolulu Star-Advertiser
Honolulu Star-Advertiser· 5 days agoAstraZeneca and Daiichi Sankyo’s Enhertu slows the progression of breast cancer by about five months...
Astrazeneca (AZN) Beats Stock Market Upswing: What Investors Need to Know
Zacks· 5 days agoFree Report) closed the most recent trading day at $78.99, moving +1.24% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.11%. Coming into today, shares of ...
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 2 days agoThe Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, signed a Memorandum of Understanding (MoU) with AstraZeneca during BIO International ...
Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.
The Wall Street Journal· 5 days agoMore patients can fend off the disease for months or years with targeted or immune-boosting drugs,...
Germany’s Merck Bets on AI Drug-Design Partnerships, Rules Out Acquisitions – Interview
The Wall Street Journal· 8 hours agoMerck—known as EMD Group in the U.S.— is betting on artificial-intelligence partnerships to develop...
ASCO24: Enhertu aims to replace Herceptin in first-line metastatic breast cancer
Pharmaceutical Technology via Yahoo Finance· 5 days agoInterim safety and efficacy results of the Phase Ib/II Destiny-BREAST07 trial with Enhertu...
Women denied ‘wonder drug’ that could double terminal breast cancer life expectancy
Daily Telegraph· 4 days agoWomen with HER2-low or ultra-low breast cancer who took Enhertu lived without their cancer growing...
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
Motley Fool via Yahoo Finance· 4 days agoAmgen is an established big pharma company with a massive pipeline and many avenues for growth...